We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.15 | 1.65% | 9.25 | 1,191,786 | 14:41:45 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.00 | 9.50 | 9.25 | 8.35 | 8.85 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.14M | -2.23M | -0.0233 | -3.97 | 8.68M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:00:31 | O | 6,705 | 9.0375 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/12/2024 | 12:18 | ALNC |  Fusion Antibodies receives approval of grant funding application |
| 04/12/2024 | 11:31 | UK RNS | Fusion Antibodies PLC Approval of Grant Funding Application |
| 19/11/2024 | 13:10 | ALNC | Fusion Antibodies interim loss narrows as revenue more than doubles |
| 19/11/2024 | 07:00 | UK RNS | Fusion Antibodies PLC Half-year Report |
| 16/10/2024 | 12:23 | UK RNS | Fusion Antibodies PLC Director/PDMR Shareholding |
| 16/10/2024 | 06:00 | UK RNS | Fusion Antibodies PLC Issue of shares to non-executive directors |
| 08/10/2024 | 12:58 | ALNC | IN BRIEF: Fusion Antibodies expects interim revenue to double |
| 08/10/2024 | 11:32 | UK RNS | Fusion Antibodies PLC Result of AGM |
| 08/10/2024 | 06:00 | UK RNS | Fusion Antibodies PLC AGM statement and trading update |
| 02/10/2024 | 06:00 | UK RNS | Fusion Antibodies PLC Block admission six monthly return |
Fusion Antibodies (FAB) Share Charts1 Year Fusion Antibodies Chart |
|
1 Month Fusion Antibodies Chart |
Intraday Fusion Antibodies Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/1/2025 | 15:00 | ☆ Fusion Antibodies: from discovery to Clinical supply ☆ | 4,548 |
| 06/1/2025 | 09:33 | Upcoming Discovery Company Webinar with ShareSoc and InvestorHub | 9 |
| 28/11/2023 | 16:25 | NEW FAB Fusion Antibodies The Next AVCT | 64 |
| 18/9/2020 | 14:23 | Fusion Antibody II | 51 |
| 17/9/2020 | 08:25 | COVID. RAPID PROGRESS MADE. Ј3M RAISED | 58 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:00:31 | 9.04 | 6,705 | 605.96 | O |
| 14:41:46 | 9.00 | 55 | 4.95 | O |
| 14:41:29 | 9.25 | 72,952 | 6,748.06 | O |
| 14:41:02 | 9.18 | 35,000 | 3,212.41 | O |
| 14:35:10 | 9.10 | 63,978 | 5,822.00 | O |
| Top Posts |
|---|
Posted at 06/1/2025 23:10 by paulsavannah TLY looks good on paper but the difference between it and FAB is that the opportunities for FAB are endless or limitless whereas with TLY they are very dependent on Govt or NHS contracts and very susceptible to competitors. I'm not saying FAB isn't either but I believe FAB will be bought over in the short to medium term and at its current price its a sitting duck. |
Posted at 06/1/2025 14:24 by fillipe Looks like a small number of large (up to 100k shares) sells have knocked the FAB price, for the moment.f |
Posted at 02/1/2025 22:02 by thiopia It's quite a bizarre claim.The main venues for ramping to the masses / great unwashed tends to Twitter or Telegram groups nowadays. There are hardly any posts on Twitter (the few who are promotional get zero to little engagement). I'm not aware of any Telegram group for FAB. As mentioned here there were hardly any posts on FAB on this thread this morning as it was moving. Part of the investment case for FAB that attracted me was the fact it was Unloved Underowned Undervalued as demonstrated by a long flat basing pattern in the share price. Not the sort of stock which appeals to rampers who love volatility. |
Posted at 02/1/2025 09:00 by gtc1508 What Adrian said:“ I don't think there is another company that has quite the technologies that Fusion has. We have a number of different offerings most other companies only have maybe one. So we're really well positioned in that regard. Answering the question how much should it be worth right now, well many times what it is today, multiples of what it is today. it’s clearly undervalued and it has been for quite at some time. in my opinion the the main reason for this seems to have been the perception that we weren't going to survive. Well we're still here. Not only that but we're now thriving we’re fitter, we're better than we were before. Alternatively maybe we would survive but we were going to require significant amounts of additional investment and dilute everybody out and probably in this Marketplace at a lower-price. That is clearly outdated and ill- founded in terms of an assessment. We don't need the money, we have no plans for an investment raise so I think those people have got it wrong and the impact on the share price is wrong and it needs correcting and we need to take that depression that's been on the share price away. I hope that the information that we shared today helps in doing that because clearly we are worth an awful lot more than the market has been suggesting.” |
Posted at 17/12/2024 06:37 by lfdkmp Have just sent the following message to FAB - will be interesting to see if, and how quickly, the slides and presentations get amended."Having researched and witnessed FAB presentations I am excited by your prospects and am now a significant shareholder. At the risk of being considered pedantic, FAB is "certified" to ISO 9001, not "accredited" to ISO 9001. The people who are "accredited" are the certification bodies (eg BSI, Lloyds Registrar, NQA etc). I used to work for one of these. Some might consider the distinction to be a moot point, but given the nature of FAB operations and business environment, you would not want to be perceived by potential or existing clients as being imprecise or tolerant of lack of exactitude." |
Posted at 14/12/2024 07:44 by bri15 Yesterday's drop was too good an opportunity to top up,glad you did ijd,i also put a few thousand more in and very happy to hold this one long term as only up share price is heading,as I posted earlier this is a multi billion $ market and big returns to be made, wish I could just switch off for 6 months and not watch daily share price movement as I know we will be far higher in price come the summer. |
Posted at 12/12/2024 19:45 by thiopia for infoGheko Posts: 991 Price: 6.90 Strong Buy Webinar Today 18:15 Great webinar presentation. A few takeaways for me. 1. The work around Optimal and Optiphage platforms. They could potentially be licensed to every biotech company in THE WORLD!! Hello, all aboard. 2.slip of the tongue when talking about the work with US National Cancer Institute. I got sense that they know it is a done deal. If that announcement comes then add then add an immediate 0 to the share price! 3. As a result of the grant funding where FAB are not paying for the equipment or upkeep they can look to grow margins. 4. When asked about potential news in next 3-6 months naturally very coy but I sensed he looking forward to lots of news. 5. Final comment was the grant gives FAB quote ‘a remarkable opportunity’. Very happy with my investment and adding more tomorrow. |
Posted at 12/12/2024 19:36 by thiopia some snippets from ShareScope webinarGheko Posts: 991 Price: 6.90 Strong Buy Webinar Today 18:15 Great webinar presentation. A few takeaways for me. 1. The work around Optimal and Optiphage platforms. They could potentially be licensed to every biotech company in THE WORLD!! Hello, all aboard. 2.slip of the tongue when talking about the work with US National Cancer Institute. I got sense that they know it is a done deal. If that announcement comes then add then add an immediate 0 to the share price! 3. As a result of the grant funding where FAB are not paying for the equipment or upkeep they can look to grow margins. 4. When asked about potential news in next 3-6 months naturally very coy but I sensed he looking forward to lots of news. 5. Final comment was the grant gives FAB quote ‘a remarkable opportunity’. Very happy with my investment and adding more tomorrow. |
Posted at 07/12/2024 11:31 by thiopia re 4214My thinking is they have had an initial informal approach from a much larger enterprise The larger enterprise want to keep all the talent on board so have made a friendly approach with a nudge nudge wink wink message something to the effect of "We'd like to buy you out but we can see your share price is nowhere near a level where you could recommend a takeover to your shareholders so we'll give you 1 year to get the share price up and then we'll offer you a premium over the 30 or 90 day Moving Average" In the meantime it gives Management etc all a chance to load up on stock and options That is my guesswork because the Management seem so confident right now and have been buying stock across the Board at regular intervals So either they know a much bigger Company is waiting in the wings or there is some operational development about to happen which should transform company US NCI platform validation and further collaboration or milestones/royalties on an antibody ? |
Posted at 24/9/2024 23:35 by bri15 JakNife all small cap companies have to raise funds,it's the nature of the industry as you know,FAB does not need to raise until around March/April next year by which time share price could be considerably higher, possibly well into double figures, hence raising funds at much higher share price than present,the company is a much better position now as i believe they have learned from past mistakes and are turning FAB around,costs cut, expenses cut,order book bright etc,etc, maybe you should buy some. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
